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Abstract
Patients with advanced stages of hepatocellular carcinoma (HCC) face a poor prognosis. Although encouraging clin-
ical results have been obtained with multikinase inhibitor sorafenib, the development of improved therapeutic strat-
egies for HCC remains an urgent goal. Aurora kinases are key regulators of the cell cycle, and their uncontrolled
expression promotes aneuploidy and tumor development. In tissue microarray analyses, we detected aurora-A ki-
nase expression in all of the examined 93 human HCC samples, whereas aurora-B kinase expression levels sig-
nificantly correlated with the proliferation index of HCCs. In addition, two human HCC cell lines (Huh-7 and HepG2)
were tested positive for aurora-A and -B and revealed Ser10 phosphorylation of histone H3, indicating an increased
aurora-B kinase activity. The antiproliferative features of a novel aurora kinase inhibitor, PHA-739358, currently under
investigation in phase 2 clinical trials for other solid tumors, were examined in vitro and in vivo. At concentrations
exceeding 50 nM, PHA-739358 completely suppressed tumor cell proliferation in cell culture experiments and strongly
decreased histone H3 phosphorylation. Cell cycle inhibition and endoreduplication were observed at 50 nM, whereas
higher concentrations led to a complete G2/M–phase arrest. In vivo, administration of PHA-739358 resulted in signif-
icant tumor growth inhibition at a well-tolerated dose. In combination with sorafenib, additive effects were observed.
Remarkably, when tumors restarted to grow under sorafenib monotherapy, subsequent treatment with PHA-739358
induced tumor shrinkage by up to 81%. Thus, targeting aurora kinases with PHA-739358 is a promising therapeutic
strategy administered alone or in combination with sorafenib for patients with advanced stages of HCC.
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Introduction
Hepatocellular carcinoma (HCC) is the fifth most common malig-
nancy worldwide and the fastest growing cause of cancer related death
in men in the United States [1,2]. Although surveillance of patients
with risk factors for HCC and development of locoregional treatment
options have improved the outcome, curative treatment consisting of
surgical resection, liver transplantation, or possibly radiofrequency
ablation is applicable to only a minority with limited stage disease
[3]. In intermediate, advanced or recurrent HCC, palliative cytotoxic
chemotherapy is mostly ineffective, and thus, patients face a very poor
prognosis. Until recently, chemoembolization was the only option to
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decelerate tumor growth. On the basis of the results of a phase 3 study
(SHARP), the multikinase inhibitor sorafenib was approved for treat-
ment of unresectable HCC [4]. Sorafenib decreases tumor cell prolif-
eration and inhibits tumor angiogenesis [5]. However, the effect is
mostly moderate, and new therapeutic strategies for advanced HCC
are mandatory.
Aurora kinases are key regulators of protein phosphorylation dur-
ing mitosis [6]. These serine/threonine kinases interact with other
proteins to control chromosome assembly and segregation. Aurora
kinases consist of three members with differences in subcellular local-
ization, kinetics of activation, and function [6]: aurora-A plays a role
in centrosome maturation and spindle assembly, aurora-B regulates
cytokinesis and chromosome cohesion as part of the spindle check-
point, whereas Aurora-C is less well studied [7].
Overexpression of aurora-A and aurora-B has been described in
several malignancies being associated with deregulation of chromo-
somal ploidy and a consecutive genetic instability. It has also been
linked to pathophysiological and clinical parameters, such as p53 ex-
pression, tumor grading, lymph node invasion, disease progression,
and survival [7]. Consequently, several small-molecule inhibitors
have been developed showing antiproliferative effects on tumor cells
in preclinical models. Recently, a highly effective aurora kinase inhibi-
tor (AKI), PHA-739358, which was shown to inhibit all aurora ki-
nases at nanomolar concentrations, has entered phase 2 clinical trials
for patients with advanced stages of prostate cancer and hematolog-
ical malignancies [8,9].
The role of aurora kinases in HCC has moved into the focus of
preclinical research. Jeng et al. [10] demonstrated up-regulation of
the aurora-A gene in HCC nodules compared with nontumorous liver
tissues. In genome-wide gene expression profiles of surgically resected
HCC, aurora-B gene expression was the only predictive factor for
HCC recurrence [11], whereas the role of aurora kinase protein ex-
pression is largely unknown. First promising in vitro and in vivo results
were yielded by VE-465, an AKI derivate of VX-680 [12]. To further
elucidate aurora-A and -B kinase protein expression in HCC, we
examined a large series of human HCC tissue samples with variable
proliferative indices by immunohistochemistry. On the basis of the
positive results, the antiproliferative features of AKI PHA-739358
were evaluated in vitro and in vivo, and possible therapeutic mecha-
nisms were analyzed. Finally, we were able to demonstrate for the first
time that combination therapy with sorafenib as well as treatment with
PHA-739358 secondary to failure of sorafenib may be an applicable
treatment strategy for patients with advanced stages of HCC.
Materials and Methods
Materials
Human-specific antibodies were used for the detection of Ki-67
(clone MIB-1); cytokeratin 18 (Dako, Hamburg, Germany); aurora-A
and aurora-B (Abcam, Cambridge, UK); and phosphorylated his-
tone H3(Ser10), caspase-3, and stathmin (Cell Signaling Technology,
Danvers, MA). PHA-739358 was provided by Nerviano Medical
Sciences Srl. (Milan, Italy). For cell culture experiments, a 10-μM stock
solution in dimethyl sulfoxide (DMSO) was prepared. For in vivo ex-
periments, an in situ salt was prepared by adding 1 μl 2N hydrochloric
acid per milligram of PHA-739358 before dissolving in 5% dextrose
at a concentration of 4.5 mg/ml. Sorafenib tosylate (purchased from
LC Laboratories, Woburn, MA) was dissolved and handled as described
in detail [13].
Tissue Microarray Construction
Tissue samples of surgically resected human HCCs or HCC nod-
ules in explanted livers were fixed in 4% buffered formalin, embed-
ded in paraffin, and used for tissue microarray (TMA) construction.
Hematoxylin-eosin (H&E)–stained sections were made from selected
primary tumor blocks (donor blocks) to define representative tumor
regions. Tissue cylinders (0.6 mm in diameter) were punched from
the representative region of the donor block using a semiautomatic
tissue arrayer [14]. Control samples included cirrhotic liver paren-
chyma. Five-micrometer sections were cut for H&E staining and
immunohistochemistry by use of the Paraffin Sectioning Aid System
(Instrumentics, Hackensack, NJ).
TMA Immunohistochemistry and Analysis
Sections were deparaffinized by warming to 60°C for 1 hour fol-
lowed by three 5-minute washes in xylene and dehydration in graded
ethanol. For antigen retrieval, slides were immersed in 10 mM citrate
buffer, pH 6.0, heated in a microwave oven for 15 minutes and cooled
for 15 minutes at room temperature (RT). For immunostaining, sec-
tions were blocked in 3% H2O2 in methanol for 10 minutes and in
bovine serum albumin in Tris-buffered saline containing 0.1% Tween-
20 (TBS-T), pH 7.4, for 1 hour and incubated with primary antibodies
in antibody diluent (Dako; Ki-67, clone MIB-1, 1:100; aurora-A,
1:100; aurora-B, 1:500) for 1 hour at RT. Sections were incubated with
peroxidase-conjugated mouse- or rabbit-specific goat immunoglobulin
G (IgG, 1:300; Real Envision HRP rabbit/mouse; Dako) for 30 min-
utes at RT with color development for 30 seconds to 10 minutes in
diaminobenzidine (Dako). Tumor spots were considered uninterpret-
able if they had insufficient tumor cells or loss of tissue in the spot.
For morphometric analysis, a magnification of ×400 was used. The
proliferation index was determined semiquantitatively by the frac-
tion of Ki-67–stained cells (low [1%-5%], moderate [5%-30%], high
[>30%]). Aurora-B staining was graded semiquantitatively from 0 (neg-
ative) to ++ (maximally positive staining intensity). Two observers
(A.Q. and D.B.) graded tissues independently, and interobserver dif-
ferences were reconciled by consensus.
Human HCC Cells and Culture
Huh-7 and HepG2 cells originating from well-differentiated hu-
man HCC tissues were maintained in Dulbecco’s modified Eagle me-
dium (Invitrogen, Karlsruhe, Germany), supplemented with 10%
fetal calf serum, 100 U/ml penicillin, and 10 μg/ml streptomycin
(Invitrogen) at 37°C in a 5% CO2 atmosphere.
Cell Analysis and Immunostaining
Cells were seeded in 24-well flat-bottomedplates (Sarstedt,Numbrecht,
Germany) at a density of 25 × 104 cells per well in 1ml of their respective
medium. Expression of aurora-A, aurora-B, and histone H3 phosphor-
ylation was determined by immunostaining cells, fixing in methanol
for 5 minutes, washing in phosphate-buffered saline (PBS), and being
postfixed in 4% paraformaldehyde for 5 minutes (staining protocol de-
scribed later). For the analysis of cell proliferation, increasing concen-
trations of PHA-739358 (dissolvent control, 5 nM to 5 μM) and/or
sorafenib (dissolvent control, 1-10 μM) were added after 24 hours of
cell culture. Approximately 48 to 120 hours later, the number of viable
cells (assessed by Trypan blue dye exclusion) was determined in triplicate
in a blinded fashion using a counting chamber under a magnification of
×200. The compound concentration that inhibits response at 72 hours
by 50% (IC50) corresponds to the fraction affected (Fa value) of 0.5. All
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tested cells were exposed to nine different concentrations of PHA-
739358 or to six concentrations of sorafenib. Immunostaining for cyto-
keratin 18 (1:50) followed the same protocol after treating cells with
50 nM PHA-739358 or DMSO for 48 hours, respectively.
Analysis of DNA Content, H3 Phosphorylation, and Apoptosis
by Flow Cytometry
Analysis of DNA content and H3 phosphorylation was performed
as previously described [9] with the following changes: Huh-7 and
HepG2 cells were plated in their respective medium and exposed to
PHA-739358 in increasing concentrations from 5 nM to 5 μM for
48 hours in all experiments. For analysis of apoptosis, cells were treated
under the same conditions. After incubation with the drugs, cells
were washed with PBS, fixed and permeabilized with FIX&PERM so-
lutions (Invitrogen), respectively stained with anti–active caspase-3
phycoerythrin-conjugated specific antibody (BD Biosciences, San Jose,
CA), and analyzed with flow cytometry.
Western Blot
Huh-7 and HepG2 cells were incubated with 50 or 500 nM PHA-
739358 in the presence or absence of fetal calf serum for 6 and
24 hours, respectively. Total proteins were extracted from cells and
untreated controls, and protein concentration was determined as
described [15]. Proteins (30 μg) were resolved by sodium dodecyl
sulfate/polyacryl gel electrophoresis (12% gel) and electrotransferred
onto nitrocellulose membranes (pore size, 0.45 μm). Immunodetection
was carried out using monoclonal and polyclonal antibodies [15]
followed by peroxidase-conjugated secondary antibodies. Detection
was performed using an enhanced chemiluminescence kit (Super
Signal West Dura Extended Duration Substrate; Thermo Scientific,
Rockford, MA).
Analysis of Stathmin Phosphorylation Status by
Two-dimensional Gel Electrophoresis
Huh-7 and HepG2 cells were treated with up to 500 nM PHA-
739358 for 48 hours or DMSO as control. Cells were lysed in sample
buffer (9 M urea, 4% CHAPS, 0.5% Resolyte [Merck, Darmstadt,
Germany], 10 μg/ml bromophenol blue). One hundred micrograms
of total protein was loaded on an immobilized pH gradient (IPG)
strip (pH 4-7, 7 cm; GE Healthcare, Solingen, Germany) by in-gel
rehydration. After isoelectric focusing (Protean IEF Cell; Bio-Rad,
Munich, Germany), immobilized pH gradient strips were equilibrated
for 2 × 15 minutes in 6 M urea, 4% sodium dodecyl sulfate, 50 mM
Tris-HCl pH 8.8 containing 1% 1,4-dithiothreitol or 4.8% iodoacet-
amide, respectively. Strips were placed on 15% sodium dodecyl sulfate/
polyacryl gel electrophoresis gels and overlaid with 0.6% agarose. After
transfer onto a polyvinylidene fluoride membrane (pore size, 0.45 μm;
Millipore, Schwalbach, Germany), gels were stained with colloidal
Coomassie to ensure equal protein loading. The membrane was incu-
bated with antistathmin antibody (1:1000) overnight at 4°C followed
by antirabbit HRP secondary antibody (Cell Signaling Technology).
Detection was performed using Pierce ECLWestern Blotting Substrate
(Thermo Scientific).
Animals
The Animal Core of the Hamburg University Medical Center pro-
vided 6- to 10-week-old nonobese diabetic/severe combined immuno-
deficiency (NOD/SCID) mice. The animals were housed and treated
under sterile conditions under a 12-hour light/12-hour dark schedule
and were fed autoclaved chow and water ad libitum. All animal ex-
periments were approved by the local authorities in accordance with
the National Institutes of Health’s Guide for Care and Use of Labo-
ratory animals.
Tumor Xenografts
Tumors resulting after subcutaneous (SC) injection of Huh-7 or
HepG2 cells in donor animals were aseptically dissected and mechan-
ically minced. Pieces of tumor tissue, approximately 5 mm3, were
transplanted SC into the experimental animals by a trocar needle.
Treatment was initiated when tumor volumes reached median sizes
of 53 to 245 mm3, and mice were assigned to treatment or con-
trol groups to obtain the closest possible mean tumor volume and
SD. Body weight and tumor volume (length × width × height ×
0.5236) were measured every 4 days using a caliper. If animals de-
veloped weight loss of more than 15% or tumor growth led to ul-
ceration or disability of animals, mice were withdrawn from the
experiments. At the end of each experiment, mice were killed under
animal welfare guidelines, and necropsy was performed. Tumors were
excised, weighed, snap frozen, and stored at −80°C.
Experimental Protocol
Experimental setting 1 (monotherapy). Mice bearing Huh-7 or
HepG2 tumors were divided into a treatment group receiving PHA-
739358 intraperitoneally at a dosage of 2 × 15 mg/kg per day or a con-
trol group receiving the same volume of vehicle solution (5% dextrose).
Experimental setting 2 (combination therapy). Mice bearing
Huh-7 tumors were divided into four groups: group 1, control, vehicle
solutions (12.5% Cremophor EL/12.5% ethanol in water by oral ga-
vage plus 5% dextrose intraperitoneally); group 2, sorafenib by oral
gavage at a dosage of 1 × 10 mg/kg per day; group 3, PHA-739358
at a reduced dosage of 1 × 15 mg/kg per day; and group 4, combina-
tion of sorafenib with PHA-739358 at the dosages used in groups 2
and 3, respectively.
Experimental setting 3 (sequential therapy). The same experi-
mental design as in experimental setting 2 was used. However, after
8 days of treatment with sorafenib, therapy was stopped, and sequen-
tial treatment with PHA-739358 at the standard dosage (2 × 15 mg/kg
per day) was initiated. Two independent experiments were performed.
Immunohistochemistry of Xenograft Tumors
Five-micrometer cryosections were fixed in acetone for 5 minutes at
4°C, washed twice for 5 minutes each in Tris-buffered saline contain-
ing 0.1% Tween-20, and blocked in H2O2 and bovine serum albu-
min. Primary antibodies (aurora-A and -B as previously mentioned,
phospho-H3S10, 1:100) were applied for 1 hour at RT. Tissue sec-
tions were washed four times in PBS for 5 minutes and incubated
with secondary antibodies (Alexa Fluor 488 goat IgG, 1:500; Cy3-
AffiniPure goat IgG, 1:500; Dako Real Envision) for 30 minutes. Sec-
tions were washed four times for 5 minutes in PBS, counterstained
with H&E or Hoechst-33258 (Molecular Probes, Eugene, OR) and
examined under light microscopy or epifluorescence, respectively.
Statistical Methods
Significance of differences was analyzed by χ 2 tests, Fisher exact
test, or 2-tailed Student’s t tests. P < .05 was considered significant.
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Results
Aurora Kinase Expression in Primary Human HCCs and
HCC Cell Lines
The TMA contained a total of 93 primary human HCC tumor
spots (Figure 1A), 89 of which were interpretable for both aurora
kinases and Ki-67 expression. Aurora-A was highly expressed in vir-
tually all HCCs with a pronounced staining in the cytoplasm in most
histospots, although nuclear staining was also observed (Figure 1B).
Weak cytoplasmic but no nuclear expression of aurora-A was found in
each of the 10 nontumorous cirrhotic control liver samples. Aurora-B
expression was strictly nuclear (Figure 1C ). A total of 21 HCCs
(23.6%) were positive for aurora-B, whereas cirrhotic livers did not
reveal aurora-B expression. The proliferation index indicated by Ki-67
expression served as a biomarker for tumor aggressiveness (Figure 1D).
Aurora-B was expressed in 3 (6.0%) of 50 low proliferating tumors
(2x +, 1x ++), in 12 (36.3%) of 33 moderately proliferating tumors
(8x +, 4x ++), and in 6 (100%) of 6 highly proliferating tumors (2x +,
4x ++; P < .001; χ 2 test 2xk table for all proliferation index groups;
P < .001, moderate vs low; P < .001, high vs low; P = .005, high vs
moderate; Fisher exact test).
The human HCC–derived cell lines Huh-7 and HepG2 were tested
positive for aurora-A and aurora-B (Figure 2). Aurora-A, which local-
izes to the centrosome during interphase until the early mitotic phase
of the cell cycle, was visible as multiple intranuclear spots, but cyto-
plasmic staining was also observed (Figure 2A). In later stages of mi-
tosis, aurora-A was located at the spindle poles (Figure 2A, arrows).
Figure 1. Human HCC TMA. Representative samples of (A) an
H&E–stained HCC tissue spot (original magnification, ×100), (B)
a HCC spot showing marked nuclear and cytoplasmic aurora-A
protein localization (original magnification, ×100), (C) a tumor spot
with strong (++) expression of aurora-B (original magnification,
×200), and (D) a respective tumor spot stained for the proliferation
marker Ki-67 (MIB-1; original magnification, ×100). Panels B to D
were counterstained with hematoxylin.
Figure 2. Aurora kinase expression in human HCC cells. (A) Huh-7 cells expressing aurora-A, which localizes to the centromeres or to the
spindle pole (arrows; see text). (B) Aurora-B expression until the metaphase is seen as diffuse brown nuclear staining in Huh-7 (large
panel) and HepG2 (insert, left cell) cells or in the spindle midzone during late mitosis (Huh-7, arrows; HepG2, insert, right cell). (C) Nu-
clear staining for phospho-H3S10 in Huh-7 and HepG2 (insert) cells quantified by flow cytometric analysis (D and E): Huh-7 (D) and
HepG2 (E) cells, double stained with propidium iodide (DNA content) and anti–phospho-H3S10. Left panels show controls; right panels
show the respective cells treated with 500 nM PHA-739358. The gates indicate phospho-H3S10–positive cells. Original magnifications:
×200 (A), ×400 (B), ×100 (C), ×600 (inserts).
Neoplasia Vol. 11, No. 9, 2009 Aurora Kinase Inhibition in HCC Benten et al. 937
Aurora-B was localized to the centromeres until metaphase and, there-
fore, was seen mainly as diffuse nuclear staining (Figure 2B). In ana-
phase and telophase, when aurora-B localizes to the spindle midzone
or midbody, it became clearly visible (Figure 2B, arrows). Aurora-A
and -B expression was confirmed by Western blot of nuclear lysates
(not shown).
Downstream target histone H3, which is phosphorylated at Ser10
(phospho-H3S10) by aurora-B during mitosis [16], was expressed in
both HCC cell lines (Figure 2C ). Quantitative analysis of phospho-
H3S10 revealed a cell fraction of 2.5% in Huh-7 and 1.3% in HepG2
cells by flow cytometry, indicating aurora-B activity in both human
HCC cell lines (Figure 2, D and E).
Inhibition of Tumor Cell Proliferation by PHA-739358
The effect of different concentrations of aurora kinase inhibition by
PHA-739358 on HCC cell proliferation was determined by Trypan
blue exclusion assay. At concentrations starting from 50 nM, PHA-
739358 led to an almost complete stop of proliferation in both Huh-7
and HepG2 cells (P < .001, Huh-7; P = .003, HepG2 at 96 hours;
Figure 3A). Analysis of the dose-response relationship revealed an ap-
proximate IC50 at 72 hours of 15 nM for Huh-7 and 20 nM for HepG2
cells. PHA-739358 treatment changed the morphology of tumor cells,
resulting in large nuclei and an increased nucleus-to-cytoplasm ratio
compared with untreated controls, suggesting that cells have under-
gone endoreduplication (Figure 3B). After withdrawal of PHA-739358
from cells treated with 500 nM for 48 hours, neither Huh-7 nor HepG2
cells restarted to grow, indicating a persistent treatment effect.
PHA-739358 Induces Endoreduplication of Tumor Cells and
Inhibits Phosphorylation of H3S10
To further elucidate the potential mechanisms of action of PHA-
739358, we next performed cell cycle analysis by flow cytometry
(Figure 4A). Significant inhibition of cell proliferation started from
50 nM, leading to endoreduplication of cells with a substantial in-
crease of the DNA content (4N and >4N fractions), whereas higher
concentrations exceeding 500 nM caused a complete G2/M–phase
arrest (Figure 4A).
Inhibition of H3S10 phosphorylation was observed in both HCC
cell lines secondary to treatment with PHA-739358 (Figures 2, D
and E , and 4B). However, although 50 nM effectively suppressed cell
Figure 3. Antiproliferative effects of PHA-739358 treatment in vitro. Left panels, Huh-7; right panels, HepG2. (A) Antiproliferative effect of
PHA-739358 in rapidly proliferating Huh-7 cells (analyzed after 96 hours) and moderately proliferating HepG2 cells (for up to 120 hours).
Significant antiproliferative effects of PHA-739358 at 50 and 500 nM compared with DMSO controls. *P < .05; **P < .01 of 50 nM/
500 nM PHA-739358 compared with controls. (B) Immunohistochemistry for cytokeratin 18 as a cytoplasmic marker of HCC cells treated
with DMSO control or 50 nM PHA-739358. Treatment with the compound for 48 hours resulted in large nuclei in Huh-7 (green) and
HepG2 cells (red) indicating endoreduplication. Original magnification, ×400; scale bars, 10 μm; counterstained with Hoechst-33258. (C)
Effects of PHA-739358 treatment for 24 hours on PARP-1 cleavage as an indicator of caspase mediated apoptosis. The 116-kDa band
indicates full-length PARP-1; the 89-kDa band represents the large fragment of PARP-1, which results only in PHA-739358–treated Huh-7
but not in HepG2 cells.
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proliferation, a significant inhibition of H3S10 phosphorylation was
only observed for concentrations exceeding 10-fold this dose level
(phospho-H3S10 cell fraction at 500 nM: Huh-7: 0.16% vs 2.50%
in controls, P < 01; HepG2: 0.06% vs 1.30%, P < .01; n = 3 each;
approximate phospho-H3S10 IC50 in both HCC cell lines, 100 nM).
Induction of apoptosis in PHA-739358–treated HCC cells was
assessed by Western blot for fragmentation of poly(ADP-ribose) poly-
merase 1 (PARP-1), a main caspase cleavage target. p53 mutated
Huh-7 cells treated with increasing concentrations of PHA-739358
for 24 hours indicated distinct PARP-1 fragmentation (Figure 3C ),
whereas the fraction of caspase-3–stained cells as assessed by flow
cytometry was only moderately increased (3.2 ± 0.4%, 4.4 ± 0.3%,
and 5.7 ± 0.7% for 50 nM, 500 nM, and 5 μM, respectively, com-
pared with 1.5 ± 0.1% in DMSO controls, P < .05). In contrast, in
p53 wild-type HepG2 cells, PHA-739358 did not lead to an increase
of PARP-1 cleavage (Figure 3C) or caspase-3–stained cell fractions.
Effects of PHA-739358 on Signaling Pathways, Cell Cycle
Regulators, and Stathmin Phosphorylation
To investigate a possible role of PHA-739358 on the mitogenic
signaling cascade as a mechanism of action, Huh-7 and HepG2 cells
were treated with various concentrations of the compound for up to
48 hours, and phosphorylation of downstream proteins was analyzed
by Western blot. Interestingly, phosphorylation of extracellular signal-
regulated kinases, protein kinase B, and c-Jun N-terminal kinases re-
mained unchanged (data not shown), indicating that inhibition of cell
proliferation by PHA-739358 was not based on altered activation of
these mitogenic pathways.
To evaluate the alternative mechanisms for the observed effects, we
analyzed the effect of PHA-739358 on cell cycle–associated proteins.
Expressions of the cyclin-dependent kinase p27, a cell cycle inhibi-
tor, and p16, which plays a crucial role in the process of cell cycle
progression at the G1/S checkpoint, were not altered (data not shown),
whereas p21, a p53-controlled regulator of cell cycle progression,
was induced by PHA-739358 treatment in p53 wild-type HepG2
cells, although it remained unchanged in p53 mutated Huh-7 cells
(Figure 4C).
G2/M–phase arrest results from perturbations of tubulin polymer-
ization as part of the cellular spindle apparatus, which is regulated by
the microtubule destabilizing protein stathmin/Op18 [17]. Because
stathmin is overexpressed in human hepatocarcinogenesis and phos-
phorylated by aurora-B [18,19], we determined the effect of PHA-
739358 treatment on stathmin phosphorylation in HCC cells. To
facilitate microtubule formation during mitosis, stathmin needs to be
inactivated by phosphorylation. After completion of mitosis, stathmin
is dephosphorylated, the spindles disintegrate, and cytokinesis can
be accomplished [20]. Two-dimensional gel electrophoresis did not
show inhibition of phosphorylation by PHA-739358 in Huh-7 cells,
whereas in HepG2 cells, which exhibited a lower baseline phosphory-
lation status compared with Huh-7 cells, PHA-739358 treatment for
48 hours led to a loss of stathmin phosphorylation compared with
DMSO-treated controls (Figure 4D).
Figure 4. Mechanisms of PHA-739358 treatment. (A) Cell cycle profile of Huh-7 cells mediated by the compound after 48 hours at the
indicated concentrations. DNA content was assessed by flow cytometry. (B) Percentage of phospho-H3S10–positive Huh-7 and HepG2
cells after treatment with DMSO or PHA-739358 at the indicated concentrations for 2 hours. Significant inhibition of phospho-H3S10
starts from PHA-739358 concentrations of 500 nM (*P < .01). (C) Western blot of lysates from HCC cells treated for 48 hours with the
indicated concentrations of PHA-739358. p21 (upper band; arrow) was only induced in p53 wild-type HepG2 cells (the lower band in
HepG2 lysates is unspecific). (D) Two-dimensional gel electrophoresis and stathmin staining of protein lysates from HCC cells treated
with 500 nM PHA-739358 for 2 hours. The small dots (arrows) indicate the two stathmin phosphorylation sites and show a loss of phos-
phorylation in HepG2 cells.
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Immunohistochemical Characterization of Tumor Xenografts
Both cell lines were injected into the flanks of immunodeficient
NOD/SCID mice. The histochemical properties of resulting tumors
resembled those of the primary cell lines. Aurora-A was expressed in
all nuclei of transplanted cells, whereas the surrounding recipient
tissue was negative for aurora-A expression (Figure 5A). Xenografts
showed aurora-B expression in 16.5 ± 5.8% and 10.6 ± 2.9% of
the nuclei in Huh-7 and HepG2 tumors, respectively (Figure 5B).
The phosphorylation status of H3S10 was slightly increased in xeno-
grafts compared with primary cells (4.3 ± 1.5%; Huh-7, 2.6 ± 1.3%;
HepG2; n = 8 tumors each; Figure 5C ).
Inhibition of Tumor Growth in Experimental Models of HCC
In experimental setting 1, treatment with PHA-739358 at a dos-
age of 2 × 15 mg/kg per day significantly decreased tumor growth of
both, rapidly proliferating Huh-7 tumors and moderately growing
HepG2 xenografts (Figure 5D). Huh-7 tumor growth was signifi-
cantly inhibited from day 3 (P < .05) until the end of the experiment
(P < .01). The mean absolute tumor volume was reduced by 80.4%,
the mean percent tumor growth was reduced by 84.4%, and the
mean tumor weight on necropsy was reduced by 71.8%, respectively,
compared with vehicle-treated controls (Figure 5D; Table 1). Anti-
proliferative efficacy was even more pronounced in HepG2 tumors
at the same dosage level (statistical details in Table 1).
In experimental setting 2, PHA-739358 in combination with
sorafenib was evaluated. In a preparatory experiment, antiprolifera-
tive efficacy of sorafenib was confirmed in Huh-7 cells in vitro and
in vivo at a dose of 30 mg/kg [21] (data not shown). Monotherapy
with both, sorafenib tosylate at a dosage of 10 mg/kg per day or with
a reduced dosage of PHA-739358 investigated for combination ther-
apy (15 mg/kg given once daily), did not lead to growth arrest but to
a significant deceleration of Huh-7 tumor proliferation (Figure 6A;
Table 1). Remarkably, the combination of PHA-739358 with sorafenib
tosylate virtually stopped growth of Huh-7 tumors completely until
treatment was terminated at day 20 (P < .001 vs PHA-739358 or vs
sorafenib alone, respectively; Table 1). After cessation of therapy, tu-
mors began to regrow, however, at a very slow rate (Figure 6A, day 24).
In experimental setting 3, one group of Huh-7 tumor-bearing mice
received the aforementioned combined treatment with PHA-739358
and sorafenib. The significantly superior effect described in experi-
mental setting 2 compared with the respective monotherapies was
confirmed (Figure 6B). To determine the impact of aurora kinase in-
hibition on HCCs, which still proliferate in vivo under sorafenib
monotherapy, sorafenib treatment was replaced on day 8 by the dosage
of PHA-739358 shown to be effective in experimental setting 1 (2 ×
15 mg/kg per day). Remarkably, this PHA-739358 “salvage” therapy
not only stopped tumor proliferation entirely but also virtually shrank
tumor volumes by up to 81% in all nine sequentially treated xenografts
(40.1 ± 25.7%; Figure 6B). Furthermore, these tumors were found to
be macroscopically and microscopically entirely necrotic (not shown).
Discussion
Recently, the SHARP trial demonstrated for the first time that tar-
geted therapy can extend overall survival in patients with HCC [4],
and as a consequence, sorafenib is currently considered the reference
criterion standard of systemic therapy [3]. However, nonresponse,
Figure 5. HCC xenograft model. (A–D) Immunohistochemistry of Huh-7 tumors grown after SC injection into NOD/SCID mice, with
specific antibodies for aurora-A (A), aurora-B (B), and phospho-H3S10 (C). Comparable results were found in HepG2 tumors (see text).
(D) PHA-739358 effectively inhibits growth of Huh-7 (D; n = 11 vs n = 10 controls) and HepG2 (n = 12 vs n = 12 controls) tumors
in vivo. Box plots indicating median, upper and lower quartiles, as well as lowest and highest observations. Small circles indicate mild
outliers; no extreme outliers were observed. PHA-739358 at a dosage of 15 mg/kg twice per day (dark gray bars) was well tolerated and
significantly suppressed tumor growth compared with vehicle-treated controls (light gray bars; see text). Different end points for the two
cell lines were due to the differential growth rate of Huh-7 or HepG2 tumors, respectively.
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Table 1. Effects of Therapy with PHA-739358 on the Growth of Human HCCs Xenografted in NOD/SCID Mice.
Experiment Initial Volume (mm3) Final Volume (mm3) Final (% Growth) Tumor Weight (mg)
Setting 1
Control (Huh-7) 60.7 ± 43.2 1182.9 ± 687.6 2175 ± 1839 1298 ± 712
PHA-739358 (Huh-7) 52.5 ± 32.4 232.1 ± 211.2† 340 ± 307† 366 ± 333*
Control (HepG2) 111.6 ± 62.7 908.7 ± 621.1 873 ± 250 1484 ± 1046
PHA-739358 (HepG2) 106.0 ± 80.7 106.4 ± 39.6‡ 137 ± 72‡ 119 ± 34‡
Setting 2
Control 291.3 ± 285.7 Treatment stopped on day 12 owing to high tumor volume
PHA-739358 1 × 15 mg/kg 245.6 ± 239.0 680.7 ± 421.9¶ 391 ± 122¶ 1183 ± 1021#
Sorafenib 1 × 10 mg/kg 212.1 ± 179.9 704.4 ± 644.2¶ 454 ± 216¶ 1326 ± 1078#
Combination 243.0 ± 139.7 256.4 ± 256.9¶ 97 ± 64¶,§ 281 ± 612#
Setting 1: Monotherapy of PHA-739358 at the standard dosage of 2 × 15 mg/kg per day.
Setting 2: Combination therapy of PHA-739358 at a reduced dosage with sorafenib.
Values were presented as mean ± SD.
*P < .05 versus controls.
†P < .01 versus controls.
‡P < .001 versus controls.
§P < .01 versus PHA-739358 and versus sorafenib, respectively.
¶Final volumes in Setting 2 were obtained on day 20 when treatment was stopped.
#Tumor weights were obtained after killing on day 24.
Figure 6. Combination therapy with PHA-739358 and sorafenib. (A) Vehicle-treated control tumors grew rapidly, and mice were killed
on day 12 after initiation of treatment because of disabling tumor burden in some animals (n = 7). PHA-739358 at a reduced dosage of
15 mg/kg per day (n = 8) and sorafenib at a dosage of 10 mg/kg per day (n = 7) decelerated tumor growth. Combination therapy with
PHA-739358 and sorafenib (n= 9) led to complete growth arrest. After cessation of combination therapy (arrow), some tumors began to
grow at a very slow rate (see Table 1 and text for statistical data). (B) The same experimental setting as in panel A was used, and the
growth arrest of tumors under combination therapy was confirmed (n = 9 in all treatment groups). However, sorafenib monotherapy
was stopped on day 8 when tumors quadrupled their size (arrow). Replacement of therapy with PHA-739358 at the standard monother-
apy dosage of 15 mg/kg twice per day from day 8 (striped boxes) until the end of the experiment induced shrinkage of tumors (see text).
All values are presented as mean +SD.
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early resistance, or intolerance to sorafenib is a significant clinical prob-
lem emphasizing the demand for additional and/or alternative treat-
ment strategies.
Overexpression of aurora kinases has been demonstrated in a va-
riety of human malignancies [7]. To assess the impact of aurora ki-
nases as a potential molecular target in HCC, we screened a TMA
consisting of a large series of human HCC tumor specimen for ex-
pression of aurora kinases. Aurora-A overexpression, an early event in
carcinogenesis, was detected in all HCCs, whereas Jeng et al. [10]
found aurora-A gene expression in only 61% of 224 HCCs studied.
Whether the nonquantitative assessment of messenger RNA cor-
relates with protein expression of aurora-A needs to be discussed
because Western blot or immunohistochemistry had not been per-
formed in this study. Interestingly, positivity for aurora-A messenger
RNA was associated with higher grading, advanced tumor stage, and
poor outcome [10].
Recent studies indicate that the inhibition of aurora-B might rep-
resent a highly promising anticancer strategy [22,23]. Here, we dem-
onstrate that aurora-B expression is significantly associated with a high
proliferation index, which has been linked to adverse clinical outcome
in HCCs [24,25]. In line with our findings in HCC, aurora-B expres-
sion was also found to correlate with tumor cell proliferation in other
malignancies resulting in higher tumor grading and a poor prognosis
[7,26,27]. Tanaka et al. [11] recently identified aurora-B gene expres-
sion in curatively resected HCCs as the most significant predictor for
aggressive tumor recurrence or genetic instability. Furthermore, valida-
tion studies even demonstrated an association of aurora-B expression
with significantly impaired survival. Notably, amplification of chromo-
somes 17q and 20q, where aurora-A and -B genes are localized, are
among the most common cytogenetic aberrations in human HCC
and have been linked to dedifferentiation [28,29].
Recently, Lin et al. [12] reported the first promising results using
high doses of AKI VE-465, an analog of VX-680. To our knowledge,
no clinical trial activity is currently being pursued with these com-
pounds. On the contrary, we evaluated here the in vitro and in vivo
efficacy of AKI PHA-739358, which has now entered phase 1/2 clin-
ical trials for relapsing chronic myeloid leukemia and metastatic pros-
tate cancer [30,31]. In vitro antiproliferative efficacy of PHA-739358
was demonstrated at nanomolar concentrations in both p53 wild-
type HepG2 cells and p53 mutated Huh-7 cells. Discrimination of
the p53 status is crucial because p53 is frequently mutated in human
HCC [32,33], and functional interaction between p53 and aurora
kinases has been described [34–36]. In fact, selective inhibition of
aurora-A provided a growth advantage in some tumor cells that ex-
perienced loss of p53 [36].
PHA-739358 significantly inhibited phosphorylation of the aurora-B
target histone H3 at concentrations exceeding 500 nM resulting in a
complete G2/M–phase arrest. In contrast, lower concentrations led to
inhibition of cell division and endoreduplication without measurably
affecting histone H3 phosphorylation. This effect has been attributed
to aurora-A inhibition with the aurora-A–regulated spindle apparatus
being the primary target. Accordingly, our analyses showed a DNA
content of 4N or more in massively enlarged nuclei of tumor cells.
Indeed, quantitative kinase inhibition assay previously demonstrated
variable sensitivity of aurora kinases for PHA-739358 (IC50 value of
13 nM for aurora-A and 79 nM for aurora-B, respectively) [8]. In a
current phase 2 clinical trial, PHA-739358 serum levels of up to
5000 nM were achievable and well tolerated in humans [37]. Thus,
considering the IC50 values outlined here, the therapeutic range of
the compound will most likely be sufficient to exert a pan-aurora ac-
tivity in vivo. Notably, high concentrations in the micromolar range
were required for in vitro effectiveness of the AKI used by Lin et al.,
which exhibits 26× stronger inhibition of aurora A compared with
aurora B. These findings might explain the more potent in vitro activity
of PHA-739358 in the cellular system.
The effect of PHA-739358 is not limited to aurora kinases but also
extends to other cellular kinases, such as Ret, fibroblast growth factor
receptors, Abl, or tyrosine kinase A [8]. To further elucidate additional
mechanisms of action in HCC, we analyzed downstream targets of
mitogenic signaling pathways, which, like aurora kinases, are phos-
phorylated at serine or threonine sites and are relevant to HCC cells
[38,39]. However, neither extracellular signal-regulated kinases (down-
stream target of Ras/Raf signaling, fibroblast growth factor recep-
tor, src), nor c-Jun N-terminal kinases (several growth factors and
cell surface receptors, src) or protein kinase B (phosphatidylinositol-3
kinase, fibroblast growth factor receptor), which has been shown to
be activated by aurora-A [40], were significantly influenced. Interest-
ingly, PHA-739358 induced apoptosis only in Huh-7 cells but not in
HepG2 cells in the concentrations used here. Similarly, Lin et al. [12]
reported apoptosis in HepG2 cells only at very high concentrations of
10 mM. This may be attributed to the variable p53 status of the two
cell lines [41,42]. Mechanistically, we found that p21, a transcriptional
target of p53 involved in experimental and human hepatocarcino-
genesis [43,44], was distinctly induced by PHA-739358 treatment
in p53 wild-type HepG2 cells but not in p53 mutated Huh-7 cells.
Because p53 is destabilized by aurora-A–dependent phosphorylation,
this may explain the differential response in these cell lines [35,45].
Gizatullin et al. [46] demonstrated that tumor cells lacking an intact
p53-p21 pathway were more likely to undergo apoptosis and endo-
reduplication in response to aurora kinase inhibition, whereas the
integrity of this pathway in some cell lines resulted in less endoredu-
plication. This may also explain why PHA-739358 inhibited stathmin
phosphorylation only in p53 wild-type HepG2 cells but not in Huh-7
cells, where stathmin is upregulated as a result of p53 mutation [19].
Stathmin is phosphorylated by aurora-B [18], overexpressed in human
hepatocarcinogenesis [19], and is of prognostic relevance for patients
with HCC [47]. Thus, inhibition of stathmin phosphorylation by
PHA-739358 may represent an additional mechanism of aurora kinase
targeting in p53 wild-type HCC cells [20].
Efficacy and toxicity of PHA-739358 were then evaluated in a SC
HCC xenograft model showing high antiproliferative activity at well-
tolerated doses. Inhibition of tumor growth in rapidly proliferating
Huh-7 tumors was highly significant although tumors continued to
grow at a very slow rate, which is comparable to the results attained
by Lin et al. [12]. To further substantiate the in vivo effectiveness of
aurora kinase inhibition in HCC, we also analyzed the effectiveness
in a second HCC cell line in vivo, that is, the more slowly proliferating
HepG2 tumors. Although complete growth inhibition was achieved
in these tumors, no significant tumor regression was observed. These
findings are in line with the moderate or missing apoptosis in Huh-7
or HepG2 cells as well as with the results from Lin et al., who observed
complete PARP cleavage in vitro but only very minor apoptosis in vivo
(<3% to 4%, depending on the dosage) [12]. In our experiments, the
combination of PHA-739358 with sorafenib showed a synergistic ef-
fect. Notably, sorafenib at the given dose of 10 mg/kg only led to a
modest slowdown of tumor growth in mice [21], a dose range com-
parable to the dosage applied in humans [4]. However, the combi-
nation of sorafenib and PHA-739358 caused a virtual growth arrest
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of HCC tumors. Furthermore, standard monotherapy dose of PHA-
739358 alone was capable of shrinking tumors even after treatment
failure under sorafenib. The in vivo mechanisms of sorafenib are well
studied, namely, vascular endothelial growth factor/platelet-derived
growth factor–mediated tumor angiogenesis and Raf kinase signaling.
The simultaneous targeting of cell cycle–associated events by PHA-
739358 may complement these mechanisms. Comparably, Villanueva
et al. [48] reported synergistic effects of proapoptotic and antiprolifera-
tive mechanisms in HCC xenografts using combined inhibition of the
mammalian target of rapamycin and epidermal growth factor receptor.
In conclusion, targeted inhibition of aurora kinases by PHA-739358,
alone or in combination, may offer a promising new approach for the
treatment of patients with advanced stage HCC. In addition, the high
efficacy of the AKI secondary to sorafenib failure raises hope for an ef-
fective second-line therapy and provides rationales for future clinical
trials using PHA-739358 in this tumor entity.
Acknowledgments
The authors thank Verena Matzat for providing expert technical as-
sistance and C. Bokemeyer for critical reading of the manuscript.
References
[1] El-Serag HB and Rudolph KL (2007). Hepatocellular carcinoma: epidemiology
and molecular carcinogenesis. Gastroenterology 132, 2557–2576.
[2] Leong TY and Leong AS (2005). Epidemiology and carcinogenesis of hepato-
cellular carcinoma. HPB (Oxford) 7, 5–15.
[3] Llovet JM and Bruix J (2008). Molecular targeted therapies in hepatocellular
carcinoma. Hepatology 48, 1312–1327.
[4] Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC,
Santoro A, Raoul JL, Forner A, et al. (2008). Sorafenib in advanced hepatocellular
carcinoma. N Engl J Med 359, 378–390.
[5] Zhu AX (2008). Development of sorafenib and other molecularly targeted
agents in hepatocellular carcinoma. Cancer 112, 250–259.
[6] Keen N and Taylor S (2004). Aurora-kinase inhibitors as anticancer agents. Nat
Rev Cancer 4, 927–936.
[7] Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN Jr, and Gandara DR
(2008). Aurora kinases as anticancer drug targets. Clin Cancer Res 14, 1639–1648.
[8] Carpinelli P, Ceruti R, Giorgini ML, Cappella P, Gianellini L, Croci V, Degrassi A,
Texido G, Rocchetti M, Vianello P, et al. (2007). PHA-739358, a potent inhibitor
of Aurora kinases with a selective target inhibition profile relevant to cancer. Mol
Cancer Ther 6, 3158–3168.
[9] Gontarewicz A, Balabanov S, Keller G, Colombo R, Graziano A, Pesenti E, Benten
D, Bokemeyer C, Fiedler W, Moll J, et al. (2008). Simultaneous targeting of
Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358
is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood
111, 4355–4364.
[10] Jeng YM, Peng SY, Lin CY, and Hsu HC (2004). Overexpression and amplifica-
tion of Aurora-A in hepatocellular carcinoma. Clin Cancer Res 10, 2065–2071.
[11] Tanaka S, Arii S, Yasen M, Mogushi K, Su NT, Zhao C, Imoto I, Eishi Y,
Inazawa J, Miki Y, et al. (2008). Aurora kinase B is a predictive factor for the
aggressive recurrence of hepatocellular carcinoma after curative hepatectomy. Br
J Surg 95, 611–619.
[12] Lin ZZ, Hsu HC, Hsu CH, Yeh PY, Huang CY, Huang YF, Chen TJ, Kuo SH,
Hsu C, Hu FC, et al. (2009). The Aurora kinase inhibitor VE-465 has anticancer
effects in pre-clinical studies of human hepatocellular carcinoma. J Hepatol 50,
518–527.
[13] Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM, and
Santoro M (2006). BAY 43-9006 inhibition of oncogenic RET mutants. J Natl
Cancer Inst 98, 326–334.
[14] Holst F, Stahl PR, Ruiz C, Hellwinkel O, Jehan Z, Wendland M, Lebeau A,
Terracciano L, Al-Kuraya K, Janicke F, et al. (2007). Estrogen receptor α (ESR1)
gene amplification is frequent in breast cancer. Nat Genet 39, 655–660.
[15] Huber S, Schrader J, Fritz G, Presser K, Schmitt S, Waisman A, Luth S, Blessing
M, Herkel J, and Schramm C (2008). P38 MAP kinase signaling is required for
the conversion of CD4+CD25− T cells into iTreg. PLoS ONE 3, e3302.
[16] Hirota T, Lipp JJ, Toh BH, and Peters JM (2005). Histone H3 serine 10 phos-
phorylation by Aurora B causes HP1 dissociation from heterochromatin. Nature
438, 1176–1180.
[17] Redeker V, Lachkar S, Siavoshian S, Charbaut E, Rossier J, Sobel A, and Curmi
PA (2000). Probing the native structure of stathmin and its interaction domains
with tubulin. Combined use of limited proteolysis, size exclusion chromatogra-
phy, and mass spectrometry. J Biol Chem 275, 6841–6849.
[18] Gadea BB and Ruderman JV (2006). Aurora B is required for mitotic chromatin-
induced phosphorylation of Op18/Stathmin. Proc Natl Acad Sci USA 103,
4493–4498.
[19] Singer S, Ehemann V, Brauckhoff A, Keith M, Vreden S, Schirmacher P, and
Breuhahn K (2007). Protumorigenic overexpression of stathmin/Op18 by gain-
of-function mutation in p53 in human hepatocarcinogenesis. Hepatology 46,
759–768.
[20] Rubin CI and Atweh GF (2004). The role of stathmin in the regulation of the
cell cycle. J Cell Biochem 93, 242–250.
[21] Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M,
and Carter C (2006). Sorafenib blocks the RAF/MEK/ERK pathway, inhibits
tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma
model PLC/PRF/5. Cancer Res 66, 11851–11858.
[22] Girdler F, Gascoigne KE, Eyers PA, Hartmuth S, Crafter C, Foote KM, Keen NJ,
and Taylor SS (2006). Validating Aurora B as an anti-cancer drug target. J Cell Sci
119, 3664–3675.
[23] Yang H, Burke T, Dempsey J, Diaz B, Collins E, Toth J, Beckmann R, and Ye X
(2005). Mitotic requirement for aurora A kinase is bypassed in the absence of
aurora B kinase. FEBS Lett 579, 3385–3391.
[24] Guzman G, Alagiozian-Angelova V, Layden-Almer JE, Layden TJ, Testa G,
Benedetti E, Kajdacsy-Balla A, and Cotler SJ (2005). p53, Ki-67, and serum α
feto-protein as predictors of hepatocellular carcinoma recurrence in liver trans-
plant patients. Mod Pathol 18, 1498–1503.
[25] Schmitt-Graff A, Ertelt V, Allgaier HP, Koelble K, Olschewski M, Nitschke R,
Bochaton-Piallat ML, Gabbiani G, and Blum HE (2003). Cellular retinol-binding
protein-1 in hepatocellular carcinoma correlates with β-catenin, Ki-67 index, and
patient survival. Hepatology 38, 470–480.
[26] Chieffi P, Cozzolino L, Kisslinger A, Libertini S, Staibano S, Mansueto G, De Rosa
G, Villacci A, Vitale M, Linardopoulos S, et al. (2006). Aurora B expression di-
rectly correlates with prostate cancer malignancy and influence prostate cell prolif-
eration. Prostate 66, 326–333.
[27] Kurai M, Shiozawa T, Shih HC, Miyamoto T, Feng YZ, Kashima H, Suzuki A,
and Konishi I (2005). Expression of Aurora kinases A and B in normal, hyper-
plastic, and malignant human endometrium: Aurora B as a predictor for poor
prognosis in endometrial carcinoma. Hum Pathol 36, 1281–1288.
[28] Midorikawa Y, Tsutsumi S, Nishimura K, Kamimura N, Kano M, Sakamoto H,
Makuuchi M, and Aburatani H (2004). Distinct chromosomal bias of gene ex-
pression signatures in the progression of hepatocellular carcinoma. Cancer Res
64, 7263–7270.
[29] Baudis M (2007). Genomic imbalances in 5918 malignant epithelial tumors: an
explorative meta-analysis of chromosomal CGH data. BMC Cancer 7, 226.
[30] PHA-739358 for treatment of hormone refractory prostate cancer. ClinicalTrials.
gov Identifier: NCT00766324. 2007.
[31] PHA-739358 in treating patients with chronic myelogenous leukemia that re-
lapsed after imatinib mesylate or c-ABL therapy. ClinicalTrials.gov Identifier:
NCT00335868. 2007.
[32] Jackson PE, Qian GS, Friesen MD, Zhu YR, Lu P, Wang JB, Wu Y, Kensler
TW, Vogelstein B, and Groopman JD (2001). Specific p53 mutations detected
in plasma and tumors of hepatocellular carcinoma patients by electrospray ioni-
zation mass spectrometry. Cancer Res 61, 33–35.
[33] Tannapfel A, Busse C, Weinans L, Benicke M, Katalinic A, Geissler F, Hauss J,
and Wittekind C (2001). INK4a-ARF alterations and p53 mutations in hepato-
cellular carcinomas. Oncogene 20, 7104–7109.
[34] Vogel C, Hager C, and Bastians H (2007). Mechanisms of mitotic cell death
induced by chemotherapy-mediated G2 checkpoint abrogation. Cancer Res 67,
339–345.
[35] Liu Q, Kaneko S, Yang L, Feldman RI, Nicosia SV, Chen J, and Cheng JQ
(2004). Aurora-A abrogation of p53 DNA binding and transactivation activity
by phosphorylation of serine 215. J Biol Chem 279, 52175–52182.
[36] Mao JH, Wu D, Perez-Losada J, Jiang T, Li Q, Neve RM, Gray JW, Cai WW,
and Balmain A (2007). Crosstalk between Aurora-A and p53: frequent deletion
or downregulation of Aurora-A in tumors from p53 null mice. Cancer Cell 11,
161–173.
Neoplasia Vol. 11, No. 9, 2009 Aurora Kinase Inhibition in HCC Benten et al. 943
[37] Paquette R, Shah N, Sawyers CL, Martinelli G, John N, Chalukya M, Rocchetti
M, Fiocchi C, Comis S, Capolongo L, et al. (2007). PHA-739358, an Aurora
kinase inhibitor, induces clinical responses in chronic myeloid leukemia har-
boring T315I mutations of BCR-ABL. Blood 110 (11, Pt 1); Abstract no. 1030.
[38] Koike K, Takaki A, Tatsukawa M, Suzuki M, Shiraha H, Iwasaki Y, Sakaguchi K,
and Shiratori Y (2006). Combination of 5-FU and IFNα enhances IFN signaling
pathway and caspase-8 activity, resulting in marked apoptosis in hepatoma cell
lines. Int J Oncol 29, 1253–1261.
[39] Saxena NK, Sharma D, Ding X, Lin S, Marra F, Merlin D, and Anania FA
(2007). Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK sig-
naling is involved in leptin-mediated promotion of invasion and migration of
hepatocellular carcinoma cells. Cancer Res 67, 2497–2507.
[40] Yang H, He L, Kruk P, Nicosia SV, and Cheng JQ (2006). Aurora-A induces cell
survival and chemoresistance by activation of Akt through a p53-dependent
manner in ovarian cancer cells. Int J Cancer 119, 2304–2312.
[41] Hsu IC, Tokiwa T, Bennett W, Metcalf RA, Welsh JA, Sun T, and Harris CC
(1993). p53 gene mutation and integrated hepatitis B viral DNA sequences in
human liver cancer cell lines. Carcinogenesis 14, 987–992.
[42] Puisieux A, Galvin K, Troalen F, Bressac B, Marcais C, Galun E, Ponchel F,
Yakicier C, Ji J, and Ozturk M (1993). Retinoblastoma and p53 tumor suppressor
genes in human hepatoma cell lines. FASEB J 7, 1407–1413.
[43] Plentz RR, Park YN, Lechel A, Kim H, Nellessen F, Langkopf BH, Wilkens L,
Destro A, Fiamengo B, Manns MP, et al. (2007). Telomere shortening and in-
activation of cell cycle checkpoints characterize human hepatocarcinogenesis.
Hepatology 45, 968–976.
[44] WillenbringH, SharmaAD,Vogel A, LeeAY, Rothfuss A,WangZ, FinegoldM, and
Grompe M (2008). Loss of p21 permits carcinogenesis from chronically damaged
liver and kidney epithelial cells despite unchecked apoptosis.Cancer Cell 14, 59–67.
[45] Dar AA, Belkhiri A, Ecsedy J, Zaika A, and El-Rifai W (2008). Aurora kinase A
inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells. Cancer
Res 68, 8998–9004.
[46] Gizatullin F, Yao Y, Kung V, Harding MW, Loda M, and Shapiro GI (2006).
The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis
preferentially in cells with compromised p53-dependent postmitotic checkpoint
function. Cancer Res 66, 7668–7677.
[47] Yuan RH, Jeng YM, Chen HL, Lai PL, Pan HW, Hsieh FJ, Lin CY, Lee PH, and
Hsu HC (2006). Stathmin overexpression cooperates with p53 mutation and
osteopontin overexpression, and is associated with tumour progression, early re-
currence, and poor prognosis in hepatocellular carcinoma. J Pathol 209, 549–558.
[48] Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, Tovar V,
Roayaie S, Minguez B, Sole M, et al. (2008). Pivotal role of mTOR signaling
in hepatocellular carcinoma. Gastroenterology 135 (6), 1972–1983; 1983.e1–e11.
944 Aurora Kinase Inhibition in HCC Benten et al. Neoplasia Vol. 11, No. 9, 2009
